The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EGFR mutation status of cell free serum DNA and clinical efficacy of afatinib in pretreated non-small cell lung cancer (NSCLC) harboring EGFR mutations.
 
Satoru Kitazono
No Relationships to Disclose
 
Hironari Nishizawa
No Relationships to Disclose
 
Hiroshi Kobayashi
No Relationships to Disclose
 
Tomoyo Oguri
No Relationships to Disclose
 
Yuichi Tambo
No Relationships to Disclose
 
Noriko Yanagitani
Honoraria - Chugai Pharma
 
Atsushi Horiike
Honoraria - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Quintiles (Inst)
 
Fumiyoshi Ohyanagi
Honoraria - Chugai Pharma; Pfizer; Taiho Pharmaceutical
 
Takeshi Horai
No Relationships to Disclose
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)